Grufity logo
Grufity logo

Latest BAKER BROS. ADVISORS LP Stock Portfolio

$19.96Billion | No. of Holdings #83

Felix & Julian Baker Performance

2026 Q2+12.98%
YTD+12.40%
2025+61.07%

About Felix & Julian Baker and 13F Hedge Fund Stock Holdings

Felix & Julian Baker is a hedge fund based in New York, NY. On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Felix & Julian Baker reported an equity portfolio of $20 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Felix & Julian Baker are INCY, BGNE, RVMD. The fund has invested 17.5% of it's portfolio in INCYTE CORPORATION and 12.6% of portfolio in BEONE MEDICINES LTD. <br><br> The fund managers got completely rid off ABIVAX S.A., SPYRE THERAPEUTICS, INC. (AGLE) and CENTESSA PHARMACEUTICALS PLC (CNTA) stocks. They significantly reduced their stock positions in EDGEWISE THERAPEUTICS, INC. (EWTX), CERUS CORPORATION (CERS) and JADE BIOSCIENCES, INC. (AVTE). Felix & Julian Baker opened new stock positions in FAETH THERAPEUTICS, INC. (SNSE), CYTOKINETICS, INCORPORATED (CYTK) and INTELLIA THERAPEUTICS, INC. (NTLA). The fund showed a lot of confidence in some stocks as they added substantially to VERASTEM, INC. (VSTM), RELAY THERAPEUTICS, INC. (RLAY) and ARCUS BIOSCIENCES, INC. (RCUS).
Felix & Julian Baker Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$19.96Billion
  as of Aug 14, 2026

Felix & Julian Baker Annual Return Estimates Vs S&P 500

Our best estimate is that BAKER BROS. ADVISORS LP made a return of 12.98% in the last quarter. In trailing 12 months, it's portfolio return was 74.08%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
faeth therapeutics, inc.32,160,300
cytokinetics, incorporated17,997,800
intellia therapeutics, inc.15,739,500
parabilis medicines, inc.13,685,000
avalyn pharma inc.11,522,000
tango therapeutics, inc.10,420,000
avalo therapeutics, inc.10,164,000
immunome, inc.1,171,930
New stocks bought by BAKER BROS. ADVISORS LP

Additions

Ticker% Inc.
verastem, inc.327
relay therapeutics, inc.143
arcus biosciences, inc.103
celldex therapeutics, inc.77.74
ideaya biosciences, inc.26.95
viridian therapeutics, inc.20.86
revolution medicines, inc.19.76
insmed incorporated18.53
Additions to existing portfolio by BAKER BROS. ADVISORS LP

Reductions

Ticker% Reduced
edgewise therapeutics, inc.-43.71
cerus corporation-36.1
jade biosciences, inc.-25.03
immatics n.v.-12.9
summit therapeutics inc.-9.91
roivant sciences ltd.-3.1
immunovant, inc.-0.42
BAKER BROS. ADVISORS LP reduced stake in above stock

Sold off

Ticker$ Sold
compass pathways plc-12,966,300
contineum therapeutics, inc.-18,556,100
spyre therapeutics, inc.-50,440,000
abivax s.a.-97,519,900
immunocore holdings plc-22,142,100
centessa pharmaceuticals plc-26,642,200
pharvaris n.v.-10,593,800
argenx se-18,383,300
BAKER BROS. ADVISORS LP got rid off the above stocks

Sector Distribution

BAKER BROS. ADVISORS LP has about 94.4% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare94.4
Others5.6

Market Cap. Distribution

BAKER BROS. ADVISORS LP has about 55.5% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • MID-CAP
  • MEGA-CAP
  • UNALLOCATED
  • SMALL-CAP
Category%
LARGE-CAP42.9
MID-CAP33.9
MEGA-CAP12.6
UNALLOCATED5.6
SMALL-CAP4.3

Stocks belong to which Index?

About 74.6% of the stocks held by BAKER BROS. ADVISORS LP either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
  • S&P 500
Index%
RUSSELL 200057.1
Others25.3
S&P 50017.5
Top 5 Winners (%)%
ABSI
absci corporation
286.3 %
ABCL
abcellera biologics inc.
113.9 %
aktis oncology, inc.
80.2 %
RVMD
revolution medicines, inc.
78.9 %
maplight therapeutics, inc.
76.3 %
Top 5 Winners ($)$
RVMD
revolution medicines, inc.
945.3 M
INCY
incyte corporation
591.7 M
KYMR
kymera therapeutics, inc.
271.7 M
ALKS
alkermes plc
170.6 M
ABCL
abcellera biologics inc.
138.0 M
Top 5 Losers (%)%
evommune, inc.
-42.2 %
TRDA
entrada therapeutics, inc.
-41.7 %
INSM
insmed incorporated
-33.0 %
TARA
protara therapeutics, inc.
-26.7 %
ALGS
aligos therapeutics, inc.
-22.3 %
Top 5 Losers ($)$
INSM
insmed incorporated
-461.4 M
SMMT
summit therapeutics inc.
-151.8 M
BGNE
beone medicines ltd.
-105.6 M
CELC
celcuity inc.
-75.4 M
TRDA
entrada therapeutics, inc.
-26.7 M

Felix & Julian Baker Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Felix & Julian Baker

BAKER BROS. ADVISORS LP has 83 stocks in it's portfolio. About 72.8% of the portfolio is in top 10 stocks. INSM proved to be the most loss making stock for the portfolio. RVMD was the most profitable stock for BAKER BROS. ADVISORS LP last quarter.

$19.96BTotal Value
92.00Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Felix & Julian Baker, last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ARGX
Argenx Se

Argenx Se

ARGX
Felix & Julian Baker's holding in Argenx Se over time
0%0.00
$0.00
0%
decreased 100 percentsold off
BNTX
Biontech Se

Biontech Se

BNTX
Felix & Julian Baker's holding in Biontech Se over time
0.06%119,743
$11.14M
0.06%
unchanged 0 percentunchanged
CMPS
Compass Pathways Plc

Compass Pathways Plc

CMPS
Felix & Julian Baker's holding in Compass Pathways Plc over time
0%0.00
$0.00
0%
decreased 100 percentsold off